

Special Issue

Advances in Ocular Pharmacology

Message from the Guest Editors

Ocular pharmacology is a field that has grown rapidly during the last few years, as we have witnessed several new and promising treatments becoming available for eye disorders that are not amenable to surgery, including age-related macular degeneration (AMD), branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), diabetic macular edema (DME), retinitis pigmentosa (RP), and virus infections. The eye is an organ protected from environmental stress and obnoxious substances by various barriers, a fact that necessitates innovation in the administration route of pharmaceutical substances. Recently several innovative technologies have been developed to directly reach the vitreous chamber or the retina. Those include intravitreal injections of anti-vascular endothelial growth factor and direct intravitreal implants, using biodegradable or non-biodegradable polymer technology. This Special Issue will summarize the state-of-the-art, and the latest findings published in the ocular pharmacology field, as well as to provide directions for future research

Guest Editors

Prof. Dr. Ioannis Tsinopoulos

2nd Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece

Dr. Ioanna Mylona

Department of Ophthalmology, General Hospital of Katerini, Katerini, Greece

Dr. Lampros Lamprogiannis

Ophthalmica Institute Thessaloniki, Thessaloniki, Greece

Deadline for manuscript submissions

closed (28 February 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/43984

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)